Report puts heart failure drug market at $8.9B by 2023

Candace Stuart | | Cardiovascular Business | Heart Failure

The market for pharmaceuticals to treat chronic heart failure could climb to nearly $9 billion over the next decade, one market research report estimated.

Decision Resources Group calculated that the market will grow from $2.9 billion in 2013 to $8.9 billion in 2023, based the prevalence of the disease and market trends. The report highlighted the pent-up demand for new therapies to treat symptoms, improve survival and reduce costly rehospitalizations.

“Pharmacological therapy for AHF [acute heart failure] has been unchanged for decades,” according to the report. “No treatment has yet been shown, convincingly, to reduce morbidity and mortality in CHF [chronic heart failure] patients with preserved ejection fraction. Recent efforts to develop new therapies for AHF and CHF have been largely unsuccessful.”

The analysis covers seven markets—the U.S., France, Germany, Italy, Spain, United Kingdom, Japan—and is based on a patient-based model. The projections include novel biologic vasodilators and other new agents that could be commercially available in coming years. These options nonetheless will face competition from less-expensive and familiar generics, the authors cautioned.

Candace Stuart, Contributor

Related Content

Medtronic using AI to identify more TAVR patients in need
Tirzepatide linked to significant weight loss, ‘impressive’ diabetes prevention after 3 years
Most heart failure patients miss out on guideline-recommended palliative care
CMS updates outpatient reimbursement policy for Barostim device
American Heart Association announces late-breaking research for Scientific Sessions 2024
Impella ECP confirmed to be safe for high-risk PCI—is FDA approval next?

Around the web

Health Imaging
Use of AI opportunistic screening in CT for cardiovascular disease

Ron Blankstein, MD, professor of radiology, Harvard Medical School, explains the use of artificial intelligence to detect heart disease in non-cardiac CT exams.

Health Imaging
New imaging protocols proposed to curb rise of cardiovascular infections

Eleven medical societies have signed on to a consensus statement aimed at standardizing imaging for suspected cardiovascular infections.

Radiology Business
What does radiology have to do with climate change?

Kate Hanneman, MD, explains why many vendors and hospitals want to lower radiology's impact on the environment. "Taking steps to reduce the carbon footprint in healthcare isn’t just an opportunity," she said. "It’s also a responsibility."